Capital-Efficient Biosimilar Development

Plenty Biologics develops highly similar versions of approved biologic medicines, using proven mechanisms and established manufacturing routes.

Our approach Our pipeline

Pipeline

Our first programme is in development.

Our first programme is an immunology monoclonal antibody. Further programmes will follow in 2027.

See the pipeline

Partnering

We are looking for commercial partners.

We are seeking commercial partners in emerging-market jurisdictions to support the commercialization of our biosimilar medicines.

Get in touch

Accessible medicines for the world

Biologics are where modern medicine has made its biggest gains in cancer, autoimmune disease and diabetes, and they reach under 20% of the world. That is a commercial failure, not a scientific one: traditional development pathways cost too much to justify serving markets that cannot reimburse at Western prices, so nobody does.

We take the other side of that trade: capital-efficient biologics development with a focus on biosimilars, built on proven mechanisms and established manufacturing routes, with cost reduction as the design goal.

Learn about our approach

~7bn

people locked out of modern biologic medicine

118

biologics lose patent protection over the next decade

$234bn

of revenue coming off patent, with few biosimilars in development

Platform